



## **Emergent BioSolutions on Track to Complete Delivery of 14.5M Doses of BioThrax to the US Government Ahead of Schedule**

May 31, 2011

ROCKVILLE, Md., May 31, 2011 (BUSINESS WIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) announced today that eight lots of BioThrax<sup>(R)</sup> (Anthrax Vaccine Adsorbed) have received regulatory release for delivery to the U.S. government under the company's contract (200-2009-30162) originally written to supply 14.5 million doses of BioThrax to the Strategic National Stockpile. This marks the largest single-week regulatory release of product for delivery in the company's history. The company expects to complete delivery of the 14.5 million doses as early as June, approximately three months ahead of the schedule originally set forth in the contract. BioThrax is the only vaccine licensed by the U.S. Food and Drug Administration (FDA) to protect against anthrax infection.

"Emergent is pleased with its progress towards early completion of its original procurement contract to supply 14.5 million doses of BioThrax," said Daniel J. Abdun-Nabi, president and chief operating officer of Emergent BioSolutions. "Upon completion of this delivery, anticipated to occur as early as June, the company will focus on delivering the additional 3.42 million doses under the modified procurement contract. With the recent request for proposal issued by the U.S. government, Emergent is also advancing discussions to supply 44.75 million doses of BioThrax over the next five years."

### **About Emergent BioSolutions Inc.**

Emergent BioSolutions protects and enhances life by developing and manufacturing vaccines and therapeutics that are supplied to healthcare providers and purchasers for use in preventing and treating disease. Emergent's marketed and investigational products target infectious diseases, oncology and autoimmune disorders. Additional information about the company may be found at [www.emergentbiosolutions.com](http://www.emergentbiosolutions.com).

### **About BioThrax**

BioThrax is the only FDA-licensed vaccine for the prevention of anthrax infection. It is indicated for the active immunization of adults who are at high risk of exposure to anthrax. BioThrax is manufactured from a culture filtrate, made from a non-virulent strain of *Bacillus anthracis*. To date, Emergent has delivered over 42 million doses of BioThrax to the U.S. government and continues to deliver additional doses under active procurement contracts. Since 1998, over 10 million doses have been administered to more than 2.5 million military personnel. For full prescribing information, please visit [www.biothrax.com/prescribinginformation\\_biothrax\\_us.pdf](http://www.biothrax.com/prescribinginformation_biothrax_us.pdf).

### **Safe Harbor Statement**

This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements, other than statements of historical fact, including statements regarding our strategy, future operations, future financial position, future revenues, projected costs, prospects, plans and objectives of management, including any potential future securities offering, our expected revenue growth and net earnings for 2011, and any other statements containing the words "believes", "expects", "anticipates", "plans", "estimates" and similar expressions, are forward-looking statements. There are a number of important factors that could cause the company's actual results to differ materially from those indicated by such forward-looking statements, including appropriations for BioThrax<sup>(R)</sup> procurement; our ability to obtain new BioThrax<sup>(R)</sup> sales contracts or modifications to existing contracts; our plans to pursue label expansions and improvements for BioThrax<sup>(R)</sup>; our plans to expand our manufacturing facilities and capabilities; the rate and degree of market acceptance of our products; the success of preclinical studies and clinical trials of our product candidates and post-approval clinical utility of our products; and other factors identified in the company's Quarterly Report on Form 10-Q for the quarter ended March 31, 2011 and subsequent reports filed with the SEC. The company disclaims any intention or obligation to update any forward-looking statements as a result of developments occurring after the date of this press release.

SOURCE: Emergent BioSolutions Inc.

Emergent BioSolutions Inc.

#### **Investors Contact:**

Robert G. Burrows  
Vice President, Investor Relations  
**301-795-1877**

[BurrowsR@ebsi.com](mailto:BurrowsR@ebsi.com)

or

#### **Media Contact:**

Tracey Schmitt  
Vice President, Corporate Communications  
**301-795-1800**

[SchmittT@ebsi.com](mailto:SchmittT@ebsi.com)